Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Qiagen N.V. stock logo
QGEN
Qiagen
$48.19
+0.3%
$44.36
$37.63
$49.30
$10.71B0.671.19 million shs631,443 shs
Repligen Corporation stock logo
RGEN
Repligen
$126.64
+1.8%
$127.95
$102.97
$182.52
$7.09B1.11727,513 shs367,089 shs
Bio-Techne Corp stock logo
TECH
Bio-Techne
$51.97
+1.0%
$49.71
$46.01
$83.62
$8.12B1.381.45 million shs1.68 million shs
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
$178.75
$176.25
$108.82
$189.99
$10.93B0.13572,759 shsN/A
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Qiagen N.V. stock logo
QGEN
Qiagen
+0.64%+2.89%+6.51%+21.68%+20.33%
Repligen Corporation stock logo
RGEN
Repligen
+0.66%+3.56%+5.71%-3.21%-1.33%
Bio-Techne Corp stock logo
TECH
Bio-Techne
-0.75%+4.36%+6.30%-10.29%-28.19%
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Qiagen N.V. stock logo
QGEN
Qiagen
3.7384 of 5 stars
1.25.00.84.52.01.71.3
Repligen Corporation stock logo
RGEN
Repligen
4.7753 of 5 stars
4.32.00.04.52.71.71.9
Bio-Techne Corp stock logo
TECH
Bio-Techne
4.9676 of 5 stars
4.25.01.74.22.81.71.9
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
0.6891 of 5 stars
0.00.00.04.50.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Qiagen N.V. stock logo
QGEN
Qiagen
2.30
Hold$49.402.51% Upside
Repligen Corporation stock logo
RGEN
Repligen
2.69
Moderate Buy$172.8336.48% Upside
Bio-Techne Corp stock logo
TECH
Bio-Techne
2.45
Hold$72.0038.53% Upside
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RGEN, QGEN, XLRN, and TECH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Qiagen N.V. stock logo
QGEN
Qiagen
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $53.00
6/24/2025
Qiagen N.V. stock logo
QGEN
Qiagen
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$55.00
6/24/2025
Repligen Corporation stock logo
RGEN
Repligen
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$150.00
6/5/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
5/30/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$59.00
5/9/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$95.00 ➝ $70.00
5/8/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$72.00 ➝ $63.00
5/8/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$75.00 ➝ $60.00
5/8/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$95.00 ➝ $75.00
5/5/2025
Repligen Corporation stock logo
RGEN
Repligen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$180.00 ➝ $180.00
4/30/2025
Repligen Corporation stock logo
RGEN
Repligen
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$202.00 ➝ $189.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Qiagen N.V. stock logo
QGEN
Qiagen
$1.98B5.42$3.23 per share14.90$16.05 per share3.00
Repligen Corporation stock logo
RGEN
Repligen
$634.44M11.21$3.18 per share39.77$35.21 per share3.60
Bio-Techne Corp stock logo
TECH
Bio-Techne
$1.16B7.03$2.32 per share22.40$13.13 per share3.96
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
$92.52M118.15N/AN/A$11.74 per share15.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Qiagen N.V. stock logo
QGEN
Qiagen
$83.59M$0.40120.7919.592.444.68%14.61%8.80%7/30/2025 (Estimated)
Repligen Corporation stock logo
RGEN
Repligen
-$25.51M-$0.45N/A53.663.54-3.93%4.53%3.17%7/29/2025 (Estimated)
Bio-Techne Corp stock logo
TECH
Bio-Techne
$168.10M$0.8263.1426.382.7410.89%13.17%10.17%8/6/2025 (Estimated)
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
-$166.03M-$4.21N/AN/AN/A-226.01%-32.11%-29.45%N/A

Latest RGEN, QGEN, XLRN, and TECH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2025Q2 2025
Repligen Corporation stock logo
RGEN
Repligen
$0.40N/AN/AN/A$174.62 millionN/A
5/7/2025Q1 2025
Qiagen N.V. stock logo
QGEN
Qiagen
$0.50$0.55+$0.05$0.41$465.66 million$483.46 million
5/7/2025Q3 2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.51$0.56+$0.05$0.14$317.92 million$316.18 million
4/29/2025Q1 2025
Repligen Corporation stock logo
RGEN
Repligen
$0.35$0.39+$0.04$0.10$163.65 million$169.17 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Qiagen N.V. stock logo
QGEN
Qiagen
N/AN/AN/AN/AN/A
Repligen Corporation stock logo
RGEN
Repligen
N/AN/AN/AN/AN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.320.62%N/A39.02%N/A
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
N/AN/AN/AN/AN/A

Latest RGEN, QGEN, XLRN, and TECH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/1/2025
Qiagen N.V. stock logo
QGEN
Qiagen
$0.250.52%7/2/20257/3/20257/10/2025
5/19/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
quarterly$0.080.67%5/19/20255/19/20255/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Qiagen N.V. stock logo
QGEN
Qiagen
0.40
3.37
2.83
Repligen Corporation stock logo
RGEN
Repligen
0.27
6.79
5.79
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.16
3.71
2.58
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
N/A
12.14
12.14

Institutional Ownership

CompanyInstitutional Ownership
Qiagen N.V. stock logo
QGEN
Qiagen
70.00%
Repligen Corporation stock logo
RGEN
Repligen
97.64%
Bio-Techne Corp stock logo
TECH
Bio-Techne
98.95%
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
90.35%

Insider Ownership

CompanyInsider Ownership
Qiagen N.V. stock logo
QGEN
Qiagen
9.00%
Repligen Corporation stock logo
RGEN
Repligen
1.20%
Bio-Techne Corp stock logo
TECH
Bio-Techne
3.90%
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
1.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Qiagen N.V. stock logo
QGEN
Qiagen
6,030222.29 million202.29 millionOptionable
Repligen Corporation stock logo
RGEN
Repligen
1,77856.18 million55.51 millionOptionable
Bio-Techne Corp stock logo
TECH
Bio-Techne
3,100156.77 million150.65 millionOptionable
Acceleron Pharma Inc. stock logo
XLRN
Acceleron Pharma
31261.16 million60.12 millionOptionable

Recent News About These Companies

Acceleron advances cold fusion technology
Acceleron Banks on Muons for Colder Fusion
Acceleron attracts turbocharged demand for debut Swissie
Merck confirms $11.5bn Acceleron takeover deal
ORBIMED CAPITAL GP II LLC's Net Worth
XLRN Historical Data
MSD eyes March FDA decision on PAH drug sotatercept
Astellas Pharma Inc
HempStreet partners with MGC Pharma launches ArtemiC
Acceleron Corp Becomes a Digital Correspondent Bank
Pharma Contract Sales Market Report 2022-2032

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Qiagen stock logo

Qiagen NYSE:QGEN

$48.19 +0.13 (+0.27%)
As of 03:24 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Repligen stock logo

Repligen NASDAQ:RGEN

$126.64 +2.26 (+1.82%)
As of 03:24 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$51.97 +0.52 (+1.02%)
As of 03:24 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Acceleron Pharma stock logo

Acceleron Pharma NASDAQ:XLRN

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.